Abstracts tagged "outcomes"

Abstract Number: 3246 • 2016 ACR/ARHP Annual Meeting
Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry
Kathleen Kolstad¹, Shufeng Li², Virginia D. Steen³ and Lorinda Chung⁴, ¹Rheumatology, Stanford Univeristy, Stanford, CA, ²Dermatology, Stanford University, Stanford, CA, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). Predictors of short-term mortality include male sex, age>60…
Abstract Number: 957 • 2016 ACR/ARHP Annual Meeting
International Patient and Physician Consensus on Psoriatic Arthritis Outcomes for Clinical Trials
Ana-Maria Orbai¹, Maarten de Wit², Philip J Mease³, Judy A. Shea⁴, Laure Gossec⁵, Ying Ying Leung⁶, William Tillett⁷, Musaab Elmamoun⁸, Kristina Callis Duffin⁹, Willemina Campbell¹⁰, Robin Christensen¹¹, Laura C. Coates¹², Emma Dures¹³, Lihi Eder¹⁴, Oliver FitzGerald¹⁵, Dafna D. Gladman¹⁶, Niti Goel¹⁷, Suzanne Grieb¹⁸, Sarah Hewlett¹⁹, Pil Hoejgaard²⁰, Umut Kalyoncu^21,22, Christine Lindsay²³, Neil J. McHugh²⁴, Bev Shea²⁵, Ingrid Steinkoenig²⁶, Vibeke Strand²⁷ and Alexis Ogdie²⁸, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Rheumatology, Paris 06 University, Paris, France, ⁶North District Hospital, Hong Kong, China, ⁷Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁹Department of Dermatology, University of Utah, Salt Lake City, UT, ¹⁰Toronto Western Hospital, Toronto, ON, Canada, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ¹²University of Leeds, Leeds, United Kingdom, ¹³Academic Rheumatology, Bristol, University of the West of England, Bristol, Bristol, United Kingdom, ¹⁴Women's College Research Institute, University of Toronto, Toronto, ON, Canada, ¹⁵Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College, Dublin, Ireland, ¹⁶Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁷Quintiles; Duke University School of Medicine, Durham, NC, ¹⁸Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ¹⁹Academic Rheumatology, University of West of England, Bristol, United Kingdom, ²⁰The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark, Denmark, ²¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²³Medical Affairs, Amgen Inc, Thousand Oaks, CA, ²⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom, ²⁵University of Ottawa, Ottawa, ON, Canada, ²⁶Patient Research Partner,, Cleveland, OH, ²⁷School of Medicine, Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: A psoriatic arthritis (PsA) core domain set to be measured in randomized controlled trials (RCT) was developed by Group for Research and Assessment…
Abstract Number: 972 • 2016 ACR/ARHP Annual Meeting
Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study
Vivien Hsu¹, Virginia D. Steen² and PHAROS Investigators, ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Rheumatology, Georgetown University Medical Center, Washington, DC
ABSTRACT: Background/Purpose: We investigated predictors of outcome, including mortality and cardiopulmonary hospitalizations in the Òat riskÓ group for pulmonary hypertension in PHAROS, a prospective longitudinal…
Abstract Number: 1003 • 2016 ACR/ARHP Annual Meeting
Ultrasonography Changes during the Course of Septic Arthritis ARE Associated with Functional Outcome
Emeline Gaigneux¹, Grégoire Cormier², Oriane Merot³, Yves Maugars⁴ and Benoit Le Goff⁴, ¹rheumatology unit, Nantes University Hospital, Nantes, France, ²rheumatology unit, Hospital, La roche sur Yon, France, ³rheumatology unit, Hospital, Saint Nazaire, France, ⁴Rheumatology, Nantes University Hospital, Nantes, France
Background/Purpose: The main goal of this study was to describe the US changes observed during the course of septic arthritis and their association with…
Abstract Number: 1062 • 2016 ACR/ARHP Annual Meeting
Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
ARSENE MEKINIAN¹, Marie Charlotte Bourrienne², LIONEL CARBILLON³, AMELIE BENBARA⁴, SYLVIE CHOLLET MARTIN⁵, AHMED TIGAIZIN³, Francois Montestruc⁶, Olivier Fain⁷ and Pascale Nicaise-Roland⁸, ¹SAINT ANTOINE HOSPITAL, PARIS, France, ²Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, ³JEAN VERDIER HOSPITAL, BONDY, France, ⁴JEAN VERDIER HOSPITAL, PARIS, France, ⁵UNITE HYPERSENSIBILITE, PARIS, France, ⁶exystat, PARis, France, ⁷Internal Medicine Department, Saint Antoine Hospital, Paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France
Background/Purpose: To describe the prevalence of non-conventional APL in patients with obstetrical APS pregnancy adverse outcome without conventional APL and the impact of treatment on…
Abstract Number: 1221 • 2016 ACR/ARHP Annual Meeting
Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative
Natalia V. Zamora¹, Maria A. Lopez-Olivo², Robin Christensen³, Niti Goel^4,5, Lars Erik Kristensen⁶, Vibeke Strand⁷, Jeffrey R. Curtis⁸, Beverly Shea⁹ and Maria Suarez-Almazor¹⁰, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁴Rheumatology Center of Excellence, Quintiles, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁷Biopharmaceutical Consultant, Portola Valley, CA, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Clinical Epidemiology & Biostatistics, McMaster University, Health Science Centre Hamilton, Ontario, ON, Canada, ¹⁰Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Patient registries both disease-and drug-based complement information obtained from clinical trials. Long-term outcomes studies can provide information useful for patients. The Agency for Healthcare…
Abstract Number: 1533 • 2016 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Women with Rheumatoid Arthritis : A Systematic Review and Meta-Analyses
Anne-Lise Gaillard¹, Thomas Barnetche² and Thierry Schaeverbeke³, ¹Rhumatologie, CHU Bordeaux Pellegrin, Bordeaux, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology Department, Bordeaux Hospital, Bordeaux, France
Background/Purpose: Actually better control of rheumatoid arthritis (RA) activity leads to new interrogations and daily questions about pregnancy. Only few studies have studied pregnancy outcomes…
Abstract Number: 1779 • 2016 ACR/ARHP Annual Meeting
Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
Manuel Ugarte-Gil^1,2, Daniel Wojdyla³, Guillermo J. Pons-Estel⁴, Luis J. Catoggio⁵, Cristina Drenkard⁶, Judith Sarano⁷, Guillermo Berbotto⁸, Eduardo Borba⁹, Emilia Sato¹⁰, Joao Carlos Brenol¹¹, Oscar Uribe¹², Luis Ramirez¹², Marlene Guibert-Toledano¹³, Loreto Massardo¹⁴, Mario Cardiel¹⁵, Luis H. Silveira¹⁶, Rosa Chacón-Díaz¹⁷, Graciela S. Alarcón¹⁸, Bernado Pons-Estel¹⁹ and GLADEL (Grupo LatinoAmericano de Estudio de Lupus), ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Cientifica del Sur, Lima, Peru, ³GLADEL consultant, Rosario, Argentina, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁸Sanatorio Británico, Rosario, Argentina, ⁹Faculdade de Medicina, Hospital das Clínicas. Universidade de São Paulo, São Paulo, Brazil, ¹⁰Rheumatology Division. Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ¹¹Hospital das Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre - RS, Brazil, ¹²Hospital Universitario “San Vicente de Paul”, Universidad de Antioquia, Medellín, Colombia, ¹³Rheumatology, Centro de Investigaciones Médico Quirúrgicas, Habana, Ciudad Habana, Cuba, ¹⁴Departments of Immunology & Rheumatology, Pontificia Universidad Católica de Chile, Santiago, Chile, ¹⁵Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ¹⁶Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ¹⁷Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ¹⁸Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁹Sanatorio Parque, Rosario, Argentina
Background/Purpose: Recently, definitions of both Remission and LLDAS have been proposed which include disease activity status and medication intake [immunosuppressive (IS) drugs and corticosteroids]. The…
Abstract Number: 1955 • 2016 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months
Benjamin Terrier¹, Christian Pagnoux², Elodie Perrodeau³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaître⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quémeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal¹⁵, Luc Mouthon¹⁵, Philippe Ravaud¹⁶ and Loïc Guillevin¹⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴Nephrology, HEGP, Paris, France, ⁵CHU Lyon, Lyon, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, Cochin Hospital, Paris, France, ⁸Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ¹³Internal Medicine, Centre Hospitalier, Niort, France, ¹⁴CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Hôpital Hôtel Dieu, Paris, France
Background/Purpose: The previously reported prospective, randomizedÐcontrolled MAINRITSAN trial compared rituximab (RTX) to azathioprine (AZA) for maintenance of ANCA-associated vasculitis (AAV) remissions obtained with a combined…
Abstract Number: 2298 • 2016 ACR/ARHP Annual Meeting
Incident Risk of Acute Gout Among Active Smokers: Data from Nationwide Inpatient Sample
Dilli Poudel¹, Paras Karmacharya¹ and Anthony Donato², ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, WEST READING, PA
Background/Purpose: Smoking has been found to be negatively correlated with serum uric acid levels by virtue of reduced production and increased consumption of endogenous anti-oxidant…
Abstract Number: 2333 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical Outcomes of Total Ankle Arthroplasty Between Biologics and NON-Biologics Treatment Groups in Patients with Rheumatoid Arthritis
Makoto Hirao¹, Kosuke Ebina², Takaaki Noguchi³, Hideki Tsuboi⁴, Jun Hashimoto⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ²Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁴Osaka Rosai Hospital, Sakai, Japan, ⁵Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: In progress of medical treatment against rheumatoid arthritis (RA) disease activity using methotrexate (MTX) and/or biologics, we often see cases that require surgical intervention…
Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Maria Hoehle, Rheumatology, Hamburg, Germany
Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
Abstract Number: 2603 • 2016 ACR/ARHP Annual Meeting
Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone
Ara H. Dikranian¹, Rubaiya Mallay², Mike Marshall³, Megan Francis-Sedlak³ and Robert J. Holt^4,5, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Suncoast Internal Medicine Consultants and Largo Med Center, Largo, FL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Medical Affairs, Horizon Pharma, Inc, Lake Forest, IL, ⁵College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL
Background/Purpose: Patients with RA have previously demonstrated significant differences in morning stiffness (MS), a debilitating symptom of RA, and other disease measures with delayed release…
Abstract Number: 224 • 2016 ACR/ARHP Annual Meeting
Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study
Angelo L. Gaffo¹, Nicola Dalbeth², Kenneth G. Saag³, Jasvinder Singh³, Elizabeth J. Rahn¹, Amy S. Mudano³, Tuhina Neogi⁴, Lorenzo Cavagna⁵, Yi-Hsing Chen⁶, Ching-Tsai Lin⁷, Worawit Louthrenoo⁸, Geraldo Castelar-Pinheiro⁹, Fernando Perez-Ruiz¹⁰, Janitzia Vazquez-Mellado¹¹, Maxim Eliseev¹², Lisa K. Stamp¹³ and William Taylor¹⁴, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁸Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁹Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ¹⁰Servicio de Reumatología, Vizcaya, Spain, ¹¹Rheumatology, Hospital General de México, Mexico City, Mexico, ¹²Research Institute of Rheumatology of Russia, Moscow, Russian Federation, ¹³University of Otago, Christchurch, New Zealand, ¹⁴University of Otago, Wellington, New Zealand
Patient Perception of Gout Flares as a Measure of Outcome: Results from an International Study Background/Purpose: Attacks (flares) are one of the primary manifestations of…
Abstract Number: 2804 • 2016 ACR/ARHP Annual Meeting
Predictors of Survival in Renal Transplantation for Lupus Nephritis – 40 Patients in 40 Years
Eleana Ntatsaki¹, Alba Velo Garcia², Borja del Carmelo Gracia Tello Sr.³, Alan D. Salama⁴ and David A. Isenberg⁵, ¹Centre for Rheumatology, University College London, London, United Kingdom, ²Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, ³Internal Medicina, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain, ⁴Centre for Nephrology, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), leading to end stage renal failure…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].